ArticleJournal for immunotherapy of cancer2026
Translational landscape of cytokine-induced killer cell therapy: an analysis based on the Informa database.
Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study maps the global clinical trial landscape of cytokine-induced killer (CIK) cell therapy across malignancies and selected immune-related disorders, based on 199 interventional trials retrieved from the Informa database up to February 2026. Analysis reveals a rapidly expanding field dominated by early-phase studies, with China leading clinical translation and academic institutions as primary sponsors. Oncology trials are most frequent, particularly in lung cancer, leukemia, and hepatocellular carcinoma, while combinatorial strategies such as dendritic cell-CIK therapy or checkpoint inhibitor combinations are increasingly explored. Adjuvant and maintenance settings predominate over neoadjuvant applications, and emerging studies indicate potential extension into autoimmune and inflammatory diseases. These findings underscore the translational potential of CIK therapy, highlight evolving combination strategies, and reveal opportunities to optimize patient stratification, standardize cell preparation, and incorporate biomarker-guided approaches. Collectively, this landscape analysis highlights key trends shaping the future clinical development of CIK-based immunotherapy and informs strategic design considerations for advancing its integration into modern oncology and immunomodulatory treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.